Upregulation of the long noncoding RNA FOXD2-AS1 predicts poor prognosis in esophageal squamous cell carcinoma.

IF 1.9

Cancer biomarkers : section A of Disease markers Pub Date : 2018-02-14 DOI:10.3233/CBM-170260

Jie Bao, Chenjie Zhou, Jiaqing Zhang, Jiaqiang Mo, Qing Ye, Junming He, Jingfang Diao

{"title":"Upregulation of the long noncoding RNA FOXD2-AS1 predicts poor prognosis in esophageal squamous cell carcinoma.","authors":"Jie Bao, Chenjie Zhou, Jiaqing Zhang, Jiaqiang Mo, Qing Ye, Junming He, Jingfang Diao","doi":"10.3233/CBM-170260","DOIUrl":null,"url":null,"abstract":"Background: The long non-coding RNA FOXD2-AS1 is highly expressed in non-small cell lung cancer and promotes malignant progression. However, the role of FOXD2-AS1 in esophageal squamous cell carcinoma (ESCC) is still unclear.Objective: In this study, we examined the relationships between the expression level of FOXD2-AS1 and the outcome of ESCC patients.Methods: Expression of FOXD2-AS1 was evaluated in cancer tissue and adjacent non-tumor tissue samples from 147 ESCC patients who received radical surgical resection using qRT-PCR. The correlations between the expression level of FOXD2-AS1 and patients' overall (OS) and disease free survival (DFS) were analyzed.Results: FOXD2-AS1 expression was upregulated in ESCC tissue than that in adjacent non-tumor tissue samples (P< 0.001). Kaplan-Meier analysis showed that high FOXD2-AS1 expression was correlated with poor prognosis in ESCC patients. Patients with a high level of FOXD2-AS1 had a shorter OS and DFS than those with a low level of FOXD2-AS1 (P= 0.005 and 0.0001, respectively). On multivariate analysis, the hazard ratio of FOXD2-AS1 expression was 1.66 (95% CI = 1.04-2.64, P= 0.033) for OS and 2.68 (95% CI = 1.49-4.82, P= 0.001) for DFS.Conclusions: Overall, our results provided convinced evidence that FOXD2-AS1 may serve as a predictive marker for ESCC patients' survival.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"527-533"},"PeriodicalIF":1.9000,"publicationDate":"2018-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-170260","citationCount":"44","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer biomarkers : section A of Disease markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-170260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 44

Abstract

Background: The long non-coding RNA FOXD2-AS1 is highly expressed in non-small cell lung cancer and promotes malignant progression. However, the role of FOXD2-AS1 in esophageal squamous cell carcinoma (ESCC) is still unclear.

Objective: In this study, we examined the relationships between the expression level of FOXD2-AS1 and the outcome of ESCC patients.

Methods: Expression of FOXD2-AS1 was evaluated in cancer tissue and adjacent non-tumor tissue samples from 147 ESCC patients who received radical surgical resection using qRT-PCR. The correlations between the expression level of FOXD2-AS1 and patients' overall (OS) and disease free survival (DFS) were analyzed.

Results: FOXD2-AS1 expression was upregulated in ESCC tissue than that in adjacent non-tumor tissue samples (P< 0.001). Kaplan-Meier analysis showed that high FOXD2-AS1 expression was correlated with poor prognosis in ESCC patients. Patients with a high level of FOXD2-AS1 had a shorter OS and DFS than those with a low level of FOXD2-AS1 (P= 0.005 and 0.0001, respectively). On multivariate analysis, the hazard ratio of FOXD2-AS1 expression was 1.66 (95% CI = 1.04-2.64, P= 0.033) for OS and 2.68 (95% CI = 1.49-4.82, P= 0.001) for DFS.

Conclusions: Overall, our results provided convinced evidence that FOXD2-AS1 may serve as a predictive marker for ESCC patients' survival.

查看原文本刊更多论文

长链非编码RNA FOXD2-AS1的上调可预测食管鳞状细胞癌的不良预后。

背景:长链非编码RNA FOXD2-AS1在非小细胞肺癌中高表达并促进恶性进展。然而，FOXD2-AS1在食管鳞状细胞癌(ESCC)中的作用尚不清楚。目的:本研究探讨FOXD2-AS1表达水平与ESCC患者预后的关系。方法:采用qRT-PCR方法对147例接受根治性手术切除的ESCC患者的癌组织及癌旁非肿瘤组织样本中FOXD2-AS1的表达进行检测。分析FOXD2-AS1表达水平与患者总生存率(OS)和无病生存期(DFS)的相关性。结果:FOXD2-AS1在ESCC组织中的表达明显高于癌旁非肿瘤组织(P< 0.001)。Kaplan-Meier分析显示，ESCC患者FOXD2-AS1高表达与预后不良相关。FOXD2-AS1高水平患者的OS和DFS均短于FOXD2-AS1低水平患者(P值分别为0.005和0.0001)。多因素分析显示，OS患者FOXD2-AS1表达风险比为1.66 (95% CI = 1.04 ~ 2.64, P= 0.033)， DFS患者FOXD2-AS1表达风险比为2.68 (95% CI = 1.49 ~ 4.82, P= 0.001)。结论:总的来说，我们的结果提供了令人信服的证据，FOXD2-AS1可以作为ESCC患者生存的预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer biomarkers : section A of Disease markers

自引率

0.00%

发文量